Shots:
- Hikma Pharmaceuticals & Celltrion have entered into exclusive licensing agreements for various biosimilar candidates across the Middle East & North Africa (MENA) region, expanding their previous partnerships
- The agreement will include the commercialization of 6 biosimilars to expand access across multiple therapeutic areas, incl. allergic diseases, ophthalmology, skeletal-related disorders, immune diseases & oncology
- As per the deal, Hikma will receive exclusive rights to commercialize the 6 biosimilars across all MENA regions, with Celltrion handling development, manufacturing & supply of the therapies
Ref: Hikma Pharmaceuticals | Image: Hikma Pharmaceuticals & Celltrion | Press Release
Related News:- Alvotech and Advanz Pharma Report the EMA’s MAA Acceptance of AVT23 (Biosimilar, Xolair)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
